This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Survival Study in Patients Undergoing On-line Hemodiafiltration (ESHOL)

This study has been completed.
Societat Catalana de Nefrologia
Information provided by (Responsible Party):
Francisco Maduell, Hospital Clinic of Barcelona Identifier:
First received: June 5, 2008
Last updated: February 27, 2014
Last verified: June 2012
Patients on hemodialysis will be randomly assigned (1:1) to continue on conventional hemodialysis or on-line hemodiafiltration, both three times per week. A 3 year follow-up and a sample size of around 750 will be necessary to detect a 35% reduction in mortality.

Condition Intervention Phase
Hemodialysis Procedure: Hemodialysis Procedure: On-line hemodiafiltration Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Study to Evaluate Survival in Patients Undergoing Hemodialysis or On-line Hemodiafiltration

Resource links provided by NLM:

Further study details as provided by Francisco Maduell, Hospital Clinic of Barcelona:

Primary Outcome Measures:
  • Survival [ Time Frame: 36 months ]

Enrollment: 906
Study Start Date: May 2007
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
Procedure: Hemodialysis
3 times per week
Experimental: B
On-line hemodiafiltration
Procedure: On-line hemodiafiltration
3 times per week


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 and older
  • Currently undergoing hemodialysis
  • Clinical stability
  • Stable vascular access

Exclusion Criteria:

  • Chronic inflammatory diseases
  • Liver cirrhosis
  • Malignancies
  • Chronic immunosuppressant or antiinflammatory use
  • Dialysis through temporary catheter or single puncture
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00694031

CSU Bellvitge
Hospitalet de Llobregat, Barcelona, Spain, 08907
Hospital Clinic de Barcelona
Barcelona, Spain, 08036
Sponsors and Collaborators
Hospital Clinic of Barcelona
Societat Catalana de Nefrologia
  More Information